In A53T mice, which have a mutation that causes early-onset and rapidly progressing Parkinsonism, ghrelin treatment resulted in a reduction in interleukin-6 and an increase in superoxide dismutase 1 (SOD1)23. Here, SOD1 is linked to Parkinson disease.